These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36991219)

  • 1. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.
    Liang Y; Wang H; Luo B
    Clin Transl Oncol; 2023 Oct; 25(10):2884-2891. PubMed ID: 36991219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
    Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
    Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
    Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
    Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
    Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
    Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
    Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
    Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
    Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
    Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
    Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
    Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
    Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
    In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
    Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
    J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.